EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment Optimization with Add-On Kampo Therapy in Highly Refractory Migraine Patients with Inadequate Response or Re-Worsening During CGRP Monoclonal Antibody Therapy: A Real-World Treatment Episode Analysis

Takafumi Tanei iD, Satoshi Yamashita iD, Satoshi Maesawa iD, Tomotaka Ishizaki iD, Takahiro Suzuki iD, Shun Yamamoto iD, Satoshi Shinoda, Toshihiko Wakabayashi, Ryuta Saito iD

Journal of Clinical Medicine · 05.11.2026 · 15 (21) · 8633

DOI: 10.3390/jcm15218633 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 05.11.2026. Verfasst von Takafumi Tanei und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Aichi, Japan. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japanese Grant-in-Aid for Scientific Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Although calcitonin gene-related peptide monoclonal antibodies (CGRP-mAbs) have improved migraine prevention, some patients continue to experience inadequate response or re-worsening during treatment. This study evaluated the effectiveness of add-on Kampo therapy in migraine patients receiving CGRP-mAb treatment.

Methods

This retrospective observational study included 39 migraine patients who received add-on Kampo therapy during ongoing CGRP-mAb treatment, contributing 55 treatment episodes. The primary endpoint was the change in monthly headache days (MHD) from baseline to 1 month after Kampo initiation. Secondary outcomes included migraine frequency, headache-related disability, quality of life, acute medication use, and work productivity. A responder was defined as achieving a ≥30% reduction in MHD at 1 month.

Results

The study population was highly refractory, with chronic migraine present in 79.5% of patients and medication-overuse headache in 56.4%. Among treatment episodes, 72.7% experienced re-worsening after an initial response to CGRP-mAb treatment. Median MHD was 14.0 days after CGRP-mAb treatment and subsequently increased to 16.0 days before Kampo initiation. After Kampo initiation, median MHD decreased to 10.0 days at 1 month. Significant improvements were also observed at 1 month in headache-related disability, quality of life, acute medication use, and presenteeism. The ≥30% and ≥50% responder rates at 1 month were 41.8% and 12.7%, respectively. Re-worsening after an initial CGRP-mAb response showed an exploratory association with treatment response in the Firth penalized logistic regression model.

Conclusions

Add-on Kampo therapy was associated with improvements in headache burden, quality of life, acute medication use, and work productivity in patients with inadequate response or re-worsening during CGRP-mAb treatment. These hypothesis-generating findings suggest a potential role for add-on Kampo therapy as a treatment optimization strategy and warrant confirmation in prospective controlled studies.

Schlagwörter

Stichwörter der Autor:innen

Kampo medicinecalcitonin gene-related peptide monoclonal antibodiesherbal medicinemedication-overuse headachemigrainere-worseningrefractory migraine

Autor:innen und Institutionen

  • Department of Neurosurgery, Nagoya University Graduate School of Medicine, Nagoya 466-8560, Aichi, Japan.
  • Specialized Headache Clinic, Nagoya Garden Clinic, Nagoya 451-0051, Aichi, Japan.
  • Department of Neurosurgery, National Hospital Organization, Nagoya Medical Center, Nagoya 460-0001, Aichi, Japan.

ORCID-Profile: Takafumi Tanei, Satoshi Yamashita, Satoshi Maesawa, Tomotaka Ishizaki, Takahiro Suzuki, Shun Yamamoto, Ryuta Saito

Förderung

  • Japanese Grant-in-Aid for Scientific Research

Zitieren

APA

Tanei, T., Yamashita, S., Maesawa, S., Ishizaki, T., Suzuki, T., Yamamoto, S., Shinoda, S., Wakabayashi, T., & Saito, R. (2026). Treatment Optimization with Add-On Kampo Therapy in Highly Refractory Migraine Patients with Inadequate Response or Re-Worsening During CGRP Monoclonal Antibody Therapy: A Real-World Treatment Episode Analysis. Journal of Clinical Medicine, 15(21), 8633. https://doi.org/10.3390/jcm15218633

Vancouver

Tanei T, Yamashita S, Maesawa S, Ishizaki T, Suzuki T, Yamamoto S, et al. Treatment Optimization with Add-On Kampo Therapy in Highly Refractory Migraine Patients with Inadequate Response or Re-Worsening During CGRP Monoclonal Antibody Therapy: A Real-World Treatment Episode Analysis. Journal of Clinical Medicine. 2026;15(21):8633. doi:10.3390/jcm15218633

BibTeX
@article{Tanei2026,
  author = {Tanei, Takafumi and Yamashita, Satoshi and Maesawa, Satoshi and Ishizaki, Tomotaka and Suzuki, Takahiro and Yamamoto, Shun and Shinoda, Satoshi and Wakabayashi, Toshihiko and Saito, Ryuta},
  title = {Treatment Optimization with Add-On Kampo Therapy in Highly Refractory Migraine Patients with Inadequate Response or Re-Worsening During CGRP Monoclonal Antibody Therapy: A Real-World Treatment Episode Analysis},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {21},
  pages = {8633},
  doi = {10.3390/jcm15218633}
}
Kostenlos starten →